F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 50 条
  • [31] The antipsychotic-like effects in rodents of YQA31 involve dopamine D3 and 5-HT1A receptor
    Gou, Hong-Yan
    Sun, Xue
    Li, Fei
    Wang, Zhi-Yuan
    Wu, Ning
    Su, Rui-Bin
    Cong, Bin
    Li, Jin
    PHARMACOLOGICAL REPORTS, 2017, 69 (06) : 1125 - 1130
  • [32] Antipsychotic-like profile, without catalepsy, of the dopamine D2/5-HT2 receptor antagonist amoxapine in the rat
    Wadenberg, ML
    Sills, TL
    Fletcher, PJ
    Kapur, S
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 317 - 317
  • [33] Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy
    Lloyd, Haydyn
    Deng, Chao
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (02) : 192 - 193
  • [34] Favourable behavioural actions of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist antipsychotic candidate
    Gyertyan, I.
    Kiss, B.
    Saghy, K.
    Laszy, J.
    Szabo, G.
    Agai-Csongor, E.
    Domany, G.
    Tihanyi, K.
    Szombathelyi, Z.
    BEHAVIOURAL PHARMACOLOGY, 2007, 18 : S12 - S13
  • [35] In vitro and in vivo neurochemical characterization of RGH-188, a potential antipsychotic with D3/D2 antagonist/partial agonist properties
    Kiss, Bela
    Schmidt, Eva
    Nemethy, Zsolt
    Horvath, Attila
    Laszlovszky, Istvan
    Gyertyan, Istvan
    Agai-Csongor, Eva
    Domany, Gyorgy
    Tihanyi, Karoly
    Szombathelyi, Zsolt
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 159S - 159S
  • [36] F17464 a new antipsychotic with preferential D3 antagonist, 5-HT1A partial agonist properties. Neurochemical studies
    Cosi, C.
    N'Guyen, V.
    Consul-Denjean, N.
    Auclair, A.
    Heusler, P.
    Martel, J. C.
    Leriche, L.
    Sokoloff, P.
    Gatti-McArthur, S.
    EUROPEAN PSYCHIATRY, 2017, 41 : S807 - S807
  • [37] The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist
    Sridhar Natesan
    Greg E. Reckless
    Karen B. L. Barlow
    John Odontiadis
    José N. Nobrega
    Glen B. Baker
    Susan R. George
    David Mamo
    Shitij Kapur
    Psychopharmacology, 2008, 199 : 275 - 289
  • [38] The antipsychotic potential of l-stepholidine -: a naturally occurring dopamine receptor D1 agonist and D2 antagonist
    Natesan, Sridhar
    Reckless, Greg E.
    Barlow, Karen B. L.
    Odontiadis, John
    Nobrega, Jose N.
    Baker, Glen B.
    George, Susan R.
    Mamo, David
    Kapur, Shitij
    PSYCHOPHARMACOLOGY, 2008, 199 (02) : 275 - 289
  • [39] AT ANTIPSYCHOTIC-LIKE EFFECTIVE DOSES, CARIPRAZINE DISPLAYS POTENT DOPAMINE D3 AND D2 RECEPTOR OCCUPANCY IN VIVO AND EFFICACY ACROSS ANIMAL MODELS
    Adham, N.
    Gyertyn, I.
    Laszlovszky, I.
    Kiss, B.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [40] Pharmacokinetics of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in rats and dogs
    Meszaros, G. Pasztor
    Bolf, E. Terjeki
    Gemesi, L.
    Kapas, M.
    Tihanyi, K.
    Szombathelyi, Z.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S456 - S457